Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
15.48
-0.12 (-0.77%)
At close: Nov 13, 2026, 4:00 PM EST
15.20
-0.28 (-1.81%)
After-hours: Nov 13, 2026, 7:45 PM EST
Nurix Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Buy" and an average price target of $33.5. The average 1-year stock price forecast is 116.41% higher than the current stock price, while the lowest is $20 (+29.20%) and the highest is $41 (+164.86%).
Price Target: $33.5 (+116.41%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 8 | 8 | 8 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 15 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $36 | Buy | Reiterates | $36 | +132.56% | Nov 5, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $35 | Buy | Maintains | $35 | +126.10% | Nov 5, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $41 | Buy | Maintains | $41 | +164.86% | Nov 4, 2026 |
| BTIG | BTIG | Buy Reiterates $32 | Buy | Reiterates | $32 | +106.72% | Nov 4, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $25 → $20 | Hold | Maintains | $25 → $20 | +29.20% | Nov 4, 2026 |
Financial Forecast
Revenue This Year
744.85M
from 83.98M
Increased by 786.93%
Revenue Next Year
123.22M
from 744.85M
Decreased by -83.46%
EPS This Year
3.02
from -3.05
EPS Next Year
-1.28
from 3.02
EPS and Forward PE are based on non-GAAP adjusted numbers.